230.42
1.81 (0.79%)
1.81 (0.79%)
Upgrade to Real-Time
Regular Market
| Volume | 486,354 |
|
|||||
| News | - | ||||||
| Day High | 231.105 | Low High |
|||||
| Day Low | 227.26 | ||||||
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Vertex Pharmaceuticals Inc | VRTX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
 |
|
|---|---|---|---|---|
| 1.81 | 0.79% | 230.42 | 10:59:47 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 228.13 | 227.26 | 231.105 | 228.61 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 11,454 | 486,354 | $ 229.43 | $ 111,581,966 | - | 176.36 - 242.99 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 10:59:47 | 10 | $ 230.43 | USD |
Period:
Draw Mode:
Vertex Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 58.58B | 254.25M | 254.11M | $ 6.21B | $ 1.77B | 10.31 | 27.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -463.00 | 0.90% |
Vertex Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical VRTX Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 227.00 | 234.58 | 226.58 | 231.22 | 1,964,143 | 3.42 | 1.51% |
| 1 Month | 222.66 | 234.58 | 214.66 | 225.42 | 1,564,075 | 7.76 | 3.49% |
| 3 Months | 181.93 | 234.58 | 179.96 | 204.99 | 1,942,491 | 48.49 | 26.65% |
| 6 Months | 196.97 | 234.58 | 176.36 | 197.99 | 1,799,091 | 33.45 | 16.98% |
| 1 Year | 237.06 | 242.99 | 176.36 | 203.90 | 1,955,947 | -6.64 | -2.8% |
| 3 Years | 193.48 | 306.08 | 163.681 | 215.69 | 1,651,802 | 36.94 | 19.09% |
| 5 Years | 81.09 | 306.08 | 80.06 | 189.64 | 1,621,641 | 149.33 | 184.15% |
Vertex Pharmaceuticals Description
| Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |